- Our Company
- CMF & Orthopedics
- Biomedical Manufacturing
- News & Events
OPM Press Releases
Now viewing articles in the category Biomedical.
Antibacterial Benefits of PEKK for Orthopedic Applications Detailed in Study of 3D-Printed OsteoFab® Structures
December 5th, 2017
The antibacterial attributes of 3D printed PEKK are significant, since they address two areas of growing concern in medicine. “Orthopedic implant infections have been steadily increasing while, at the same time, antibiotics developed to kill such bacteria have proven less and less effective with every passing day,” according to the researchers. “It is clear that new approaches that do not rely on the use of antibiotics are needed to decrease medical device infections.” As a result, the antibacterial properties detailed in this new study that apply to OsteoFab devices will provide another important layer of differentiation for the performance of OPM medical devices in the marketplace.
April 10th, 2017
South Windsor, CT, April 10, 2017 - Oxford Performance Materials, Inc. (OPM), a leader in advanced materials science and high performance additive manufacturing (HPAM™), today announced that Severine Zygmont, President of OPM Biomedical, will present at the 2017 Design of Medical Devices Conference on Wednesday, April 12th, during the 3D Printing session taking place from 10:30 – 12:00 CST in the Meridian Ballroom 4 at The Commons Hotel in Minneapolis.
March 13th, 2017
Oxford Performance Materials, Inc. (OPM), a leader in advanced materials science and high performance additive manufacturing (HPAM™), today announced that it has received a Notice of Decision to Grant a Patent from the European Patent Office (EPO) for OPM’s invention on a "Customized Implant for Bone Replacement”, which leverages its OsteoFab® implant manufacturing process, originally filed on December 5, 2011. The patent, which took effect on December 21, 2016, will be valid until August 7, 2029, and enables OPM to apply its high-performance additive manufacturing process to 3D print customized implants for bone replacement.
March 8th, 2017
Oxford Performance Materials, Inc. (OPM) announced that it has been named one of Fast Company’s Most Innovative Companies of 2016, an annual list honoring leading enterprises and rising newcomers that exemplify the best in nimble business and impactful innovation. OPM was selected as one of the Most Innovative Companies by sector in the biotech category for the Company’s first-in-kind SpineFab® VBR implant system, which received 510(k) clearance from the FDA in July of 2015.
July 23rd, 2015
Oxford Performance Materials, Inc. (OPM), a leading advanced materials and additive manufacturing (3D printing) company, today announced that it has received 510(k) clearance from the FDA for its first-in-kind SpineFab® VBR implant system. OPM’s SpineFab system is the first and only FDA cleared 3D printed load-bearing polymer device for long-term implantation and represents OPM’s third successful OsteoFab regulatory clearance.
March 10th, 2015
Today's panel discussion at the Piper Jaffray Technology, Media & Telecommunications Conference in New York City highlighted the shift in 3D Printing from prototyping to high performance additive manufacturing.
November 19th, 2014
Oxford Performance Materials Inc. has revealed it has received a three-year $150,000 grant from the National Institutes of Health to deliver new approaches in the treatment of infections related to implanted devices from advanced applications of 3D printed poly-ether-ketone-ketone.
October 29th, 2014
First-of-its-Kind Collaboration Combines Advanced Materials Science, 3D Printing, and Biomedical & Clinical Expertise in a Broad Strategic Partnership to Deliver Patient-Specific Solutions and Other Biomedical Products
September 16th, 2014
Oxford Performance Materials Inc. (OPM), a leading advanced materials and additive manufacturing (3D printing) company, today announced the appointments of Bernie Plishtin as Chief Business Development Officer and Tony DeCarmine as Chief Technology Officer.
August 19th, 2014
Oxford Performance Materials, Inc. (OPM), a leading advanced materials and additive manufacturing (3D printing) company, has been named the “Best Global Company for 3D Healthcare Innovation” by The New Economy Awards. The New Economy Awards, presented by The New Economy Magazine, identify and celebrate innovative companies that are breaking new ground in the areas of technology, energy, business and strategy.
August 19th, 2014
Oxford Performance Materials, Inc. (OPM), a leading advanced materials and additive manufacturing (3D printing) company, today announced that it has received 510(k) clearance from the FDA for its 3D printed OsteoFab® Patient-Specific Facial Device (OPSFD). OPM’s facial device is the first and only FDA cleared 3D printed polymeric implant for facial indications, and follows FDA clearance of the first and only 3D printed polymeric implant, OPM’s OsteoFab Patient-Specific Cranial Device, which was granted in February 2013.
August 4th, 2014
Oxford Performance Materials, Inc. (OPM), a leading advanced materials and additive manufacturing (3D printing) company, today announced the appointment of Severine Zygmont and Paul Martin as Presidents of OPM Biomedical and OPM Aerospace & Industrial divisions, respectively.
April 8th, 2013
Oxford Performance Materials (OPM) and Biomet Microfixation (Biomet) have entered into an exclusive distribution agreement for OPM’s OsteoFab™ Patient Specific Cranial Device (OPSCD). Under the terms of the agreement, Biomet will have exclusive global distribution rights to the OPSCD and OsteoFab™ implants for craniomaxillofacial (CMF).
February 18th, 2013
Oxford Performance Materials (OPM) is pleased to announce it has received FDA 510(k) clearance for the OsteoFab™ Patient Specific Cranial Device (OPSCD). “OsteoFab” is OPM’s brand for Additively Manufactured medical and implant parts produced from PEKK polymer. With OPM’s Additive Manufacturing process (also called “3D Printing”), implants are “grown” layer by layer directly from a digital CAD file without the aid of tooling and with few practical limits on what can be produced. FDA clearance of this device marks the first approval for an additively manufactured polymer implant.
August 22nd, 2012
Oxford Performance Materials has been selected as part of a team to participate in the National Additive Manufacturing Innovation Institute (NAMII). NAMII is the pilot institute for the National Network for Manufacturing Innovation (NNMI), the initiative announced by President Obama in March 2012. OPM will work as part of a larger team of universities, companies, and organizations led by the National Center for Defense Manufacturing and Machining (NCDMM).
July 30th, 2012
Oxford Performance Materials (OPM) has acquired the rights to modify and advance the Structured Light Scanning (SLS) system developed by Connecticut Center for Advanced Technology, Inc. (CCAT). The technology was designed by CCAT under a U.S. Air Force research contract to produce 100% optical measurement of highly complex, light-weight, efficient structures. OPM is at the forefront of creating such complex structures via additive manufacturing in both biomedical and industrial markets.
November 29th, 2011
Oxford Performance Materials is pleased to announce that an innovative spinal device made from OXPEKK®-IG has recently received regulatory approvals in two South American countries. Following great success in Europe, the FILL-SQUALE™ cervical cage has been approved for long-term implantation by ANMAT and DIGEMID, the regulatory authorities in Argentina and Peru, respectively.
October 9th, 2011
OsteoFab, a division of Oxford Performance Materials (OPM) of South Windsor, Connecticut has manufactured and shipped its first patient-specific implant. According to OPM President Scott DeFelice, the custom-designed implant is made by a selective laser sintering machine from a polymer called polyetherketoneketone or PEKK.
July 5th, 2011
OPM is very pleased to announce it has secured funding for the purchase of an EOSINT P 800 SLS machine for the production of the firm's OsteoFab™ medical implants. The funding was provided by the Connecticut Innovations, Inc.'s BioScience Facilities Fund.